News

Yang Se Jong Transforms Into A Small-Time Crook Chasing A Sunken Treasure In “Low Life”
Disney+’s upcoming original series “Low Life” has shared more insights into Yang Se Jong's character! Based on the webtoon of ...
ABC7 New York22h
All 7 BTS members are now done with mandatory service
In South Korea, all able-bodied men aged 18 to 28 are required by law to perform 18-21 months of military service under a ...
Sportschosun on MSN2d
44-year-old Song Hye-kyo admires the combination of long hair and pink dress..He's so beautiful again
Actor Song Hye-kyo proved her legendary beauty by transforming into long hair.Song Hye-kyo posted a photo taken in Madrid, Spain on the 19th.Song Hye-kyo, who attended an event, is wearing a pink ...
Sportschosun on MSN2d
Song Hye-kyo's long hair style changed a lot from her comeback short cut
Actor Song Hye-kyo reported on his recent situation in Madrid, Spain.Song Hye-kyo posted several photos on the 18th with the ...
Liverpool Echo15d
Simple pencil trick show whether you look better with long or short hair
A hair care guru has shared a 'fool proof' trick to tell whether you'd look better with long or short hair. Amy Chang, who is known as @bondenavant on social media, has shared a nifty trick with ...
AdnKronos16d
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease ...
McKnight's Long-Term Care News16d
States sue over termination of $11B in COVID-era grants
Stephen Hanse, president and CEO of the New York State Health Facilities Association/New York State Center for Assisted Living, told McKnight’s Long-Term Care News that the states’ lawsuit ...
Malaysian Reserve16d
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ — New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying ...